be_ixf;ym_202207 d_01; ct_50

Clinical Research Studies

Improving the health of our patients through groundbreaking clinical research.

The Schweiger Dermatology Group (SDG) Clinical Research Department Research Clinic is led by Dr. David Goldberg, founder of Skin, Laser and Surgery Specialist of New York and New Jersey. Dr. Goldberg brings more than 25 years of experience in conducting large multi-center clinical trials on a wide variety of cosmetic and medical devices, as well as pharmaceutical treatments. Our research team is committed to responsible research conducted under strict industry and safety standards.

Current Dermatology Clinical Trials

Study: Injectable Treatment to Treat Keloids

Purpose: To assess the safety, tolerability, and efficacy of various doses of STP705 (10μg, 20μg, 30μg and 40μg) intradermal injection and placebo, when injected into the keloid excision site, to prevent the recurrence of keloids following their excision. The study treatments are administered once per week. There will be four (4) follow-up visits at one (1), three (3), six (6) and nine (9) months after your keloid surgery.

Qualifications:

  • Male and Females, 18 – 60 years old
  • Have at least one keloid scar present for at least one year on the upper body, arms, or legs

Duration: 54 weeks
Location: Hackensack, NJ
Compensation: Up to $1,100 if all study visits are completed

Interested in participating in our clinical research study? Please click here.


Study: Evaluation of the Mind.Px Patch on Response to Biologic Treatment for Patients with Plaque Psoriasis

Purpose: The purpose of this study is to evaluate the impact of Mind.Px on response to biologic treatment for patients suffering from plaque psoriasis, as judged by the mean change in the Psoriasis Area Severity index (PASI) score from baseline to end of Week 16 of the study.

Qualifications:

  • Male and Females, 18 years or older
  • Current diagnosis of Plaque Psoriasis

Duration: Up to 20 weeks
Locations: Hackensack, NJ
Compensation: Up to $630 will be paid to the patient *once all visits are completed*

Interested in participating in our clinical research study? Please click here.


Study: Safety and Efficacy of Sofwave Treatment for Acne Scars Appearance Improvement

Purpose: To evaluate the clinical efficacy of SofWave treatment to improve acne scars appearance. Eligible patients will receive 3 treatments (4-6 weeks apart) on the facial acne scars using Sofwave System. All patients will return to the clinic for one follow up visit at 3 months post last treatment.

Qualifications:

  • Female and male subjects, ages 22 to 80 years
  • Mild to moderate facial acne scars

Duration: Approx. 6 months
Locations: Hackensack, NJ
Compensation: Up to $120 will be paid to the patient *once all visits are completed*

Interested in participating in our clinical research study? Please click here.


Study: Evaluation of the risk of atrophic acne scar formation during treatment of acne vulgaris subjects with trifarotene 50 μg/g cream versus vehicle cream

Purpose: The purpose of this trial is to evaluate the effect of trifarotene 50 μg/g cream versus vehicle cream on the risk of formation of atrophic acne scars in facial acne subjects. This is a randomized, double-blind, vehicle-controlled clinical study using a split-face design for intra-individual comparison (right half-face versus left half-face).

Qualifications:

  • Male and Females, 17 to 35 years old
  • Clinical diagnosis of Acne Vulgaris on the face (minimum of 20 inflammatory lesions and minimum of 10 atrophic acne scars)
  • Symmetrical number of lesions/scars on the whole face (i.e. no more than twice as many lesions/scars of each type on one half of the face than on the other half)

Duration: Up to 24 weeks
Locations: Hackensack, NJ
Compensation: Up to $1,450

Interested in participating in our clinical research study? Please click here.


Study: Efficacy and Safety study of RPT193 as Monotherapy in Adults with Moderate-to-Severe Atopic Dermatitis

Purpose: This study is being done to evaluate the safety and tolerability of RPT193 in subjects with moderate to severe atopic dermatitis, also known as eczema. Investigational product will be administered as monotherapy for AD in adult patients who have had an inadequate response to topical medications for AD (e.g., corticosteroids) or who are otherwise unable to take topical medications.

Qualifications:

  • Male and Females, 18 to 75 years old
  • Clinical diagnosis of Atopic Dermatitis
  • Documented history of inadequate response to a ≥1 month treatment with topical medications

Duration: Up to 7 months
Locations: Hackensack, NJ
Compensation: Up to $650

Interested in participating in our clinical research study? Please click here.

Interested in participating in our clinical research study?

Please click here


What to expect during a clinical trial:

  • Access to new investigational treatments before they are made widely available
  • Financial compensation for participation
  • An opportunity to contribute to the advancement of medical science through research
  • Study visits conducted by a trained and dedicated research team
  • Adherence to strict industry and safety standards.
  • Evaluations performed by one of our certified providers

To learn more contact: Diana Aranzazu, research@schweigerderm.com, 609-219-5621

About Schweiger Dermatology Group

Schweiger Dermatology Group was founded to help make excellent dermatology care accessible throughout the Northeast. In 2010, Dr. Eric Schweiger started the practice with a single location in Midtown Manhattan. When he saw the need for high-quality dermatology care that did not require weeks or months of waiting to see a qualified provider, his vision of a multi-location practice was born.

Back to Top
>

Receive skincare tips, news and special offers!

Field marked with asterisk (*) is mandatory.